Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 9Breast Neoplasms 8Triple Negative Breast Neoplasms 7Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Osteosarcoma 2Uterine Cervical Neoplasms 1Sarcoma, Ewing 1Pathologic Complete Response 1Neutropenia 1Neoplasms 1NSCLC 1Myelosuppression 1Limited Stage Small Cell Lung Cancer 1Hemangiosarcoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Advanced Squamous Non-Small-Cell Lung Cancer 1

Interventions

durvalumab 2Radiotherapy 2Etoposide 2Drug Therapy 2Cisplatin 2trilaciclib 1tislelizumab 1pamiparib 1anlotinib 1Tirapazamine 1Surgical Procedures, Operative 1Sodium Chloride 1Radiation Dose Hypofractionation 1Radiation 1Probiotics 1Magnetic Resonance Spectroscopy 1Immunotherapy 1Glucose 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Limited Stage Small Cell Lung Cancer × trilaciclib × Clear all
NCT07473128 2026-03-16

Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

Pharmacosmos A/S

Phase 3 Not yet recruiting
120 enrolled
Thoracic

Limited Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡